Salmonella Treatment and Prevention

Most Salmonella infections in healthy adults clear on their own within a week. But that statement hides real complexity: for invasive infections, typhoid fever, and certain high-risk patients, the right treatment choice — or the wrong one — can mean the difference between recovery and a life-threatening complication. This hub covers everything from oral rehydration salts at home to IV ceftriaxone in the ICU, plus vaccines and food-safety practices that prevent infection in the first place.

  1. Treatment by Disease Type
  2. Oral Rehydration as the Cornerstone
  3. When NOT to Give Antibiotics
  4. When Antibiotics ARE Indicated
  5. Typhoid Treatment Overview
  6. Vaccination for Prevention
  7. Food Safety and Source Control
  8. Special Populations
  9. Key Research Papers
  10. Connections
  11. Featured Videos

1. Treatment by Disease Type

There is no single "Salmonella treatment." Three clinically distinct syndromes caused by Salmonella require three very different management approaches, and collapsing them into one protocol causes real harm — either unnecessary antibiotic prescribing that promotes resistance and prolongs carriage, or dangerous under-treatment of invasive disease.

Non-typhoidal Salmonella (NTS) Gastroenteritis

This is the familiar food-poisoning form: diarrhea, nausea, cramps, and sometimes fever lasting 3–7 days. In immunocompetent adults, the cornerstone of management is fluid and electrolyte replacement only. Antibiotics are not routinely indicated and in most cases actively harmful — they extend the period of fecal shedding, select for resistant strains, and provide no meaningful symptom benefit. Recovery without antibiotics is essentially universal in healthy people.

Invasive Non-typhoidal Salmonella (iNTS)

When Salmonella crosses the gut wall and enters the bloodstream — bacteremia — the equation reverses completely. This occurs most often in sub-Saharan Africa in children under five with malnutrition or malaria, and globally in adults with HIV, sickle cell disease, or other immunosuppression. iNTS carries a case-fatality rate of 20–25% in many African settings. These patients require prompt intravenous antibiotics, typically third-generation cephalosporins (ceftriaxone) or fluoroquinolones depending on local resistance patterns.

Typhoid Fever (Salmonella Typhi and Paratyphi)

Typhoid is a systemic illness, not primarily a gut illness. S. Typhi invades macrophages and disseminates through the reticuloendothelial system. Every confirmed or clinically suspected case of typhoid fever requires antibiotic treatment — period. Untreated typhoid carries a mortality of 10–30%; appropriate treatment reduces that to under 1%. The choice of antibiotic depends heavily on local and travel-acquired resistance patterns, which have shifted dramatically over the past two decades.

Back to Table of Contents

2. Oral Rehydration as the Cornerstone

Dehydration — not the bacteria itself — kills most people who die from Salmonella gastroenteritis. Restoring fluid and electrolyte balance is the primary and often only treatment needed. The key is that plain water is not enough, and sports drinks are not a substitute for proper oral rehydration salts (ORS).

Why Plain Water Fails

Diarrhea losses are rich in sodium, potassium, and bicarbonate. Replacing volume with water alone dilutes serum electrolytes, potentially worsening hyponatremia. More critically, glucose-coupled sodium absorption in the small intestine is preserved even when the secretory diarrhea mechanism is overwhelmed — a phenomenon that forms the scientific basis of ORS. You need both glucose and sodium together to drive absorption efficiently.

WHO-Recommended ORS Formula

The World Health Organization low-osmolarity ORS formula contains:

Pre-packaged ORS sachets (sold as Pedialyte, Hydralyte, and generic WHO-formula packets) reliably deliver this composition. Mix one sachet with exactly one liter of safe water — diluting more risks under-dosing sodium.

Rice-Based ORS

Rice-based ORS substitutes rice powder for glucose. Studies show that rice-based ORS reduces stool output by approximately 30% compared to glucose-based ORS in cholera, and provides comparable benefit in other secretory diarrheas including Salmonella. Rice starch hydrolyzes slowly to glucose in the gut lumen, providing sustained glucose-coupled sodium absorption with lower osmotic load. It is not always available pre-packaged, but can be made at home by boiling 50g of rice flour in one liter of water with 3.5g of salt (approximately 3/4 teaspoon).

Why Sports Drinks Are Not Adequate

A common emergency room conversation: "I've been drinking Gatorade." Sports drinks contain approximately 20 mEq/L sodium — roughly one-quarter to one-third of what ORS delivers — and far more sugar than ORS, creating an osmotic load that can worsen diarrhea. They were designed to replace sweat losses during exercise, not to manage infectious diarrhea. Gatorade and similar drinks are not harmful in mild illness when someone can tolerate food, but they are not a substitute for ORS in moderate-to-severe dehydration.

Assessing Dehydration Severity

Mild dehydration (less than 5% body weight lost): thirst, slightly dry mouth — treat with ORS at home, about 50 mL/kg over 4 hours plus replacement of ongoing losses. Moderate dehydration (5–10%): dry mucous membranes, sunken eyes, reduced skin turgor, decreased urine — ORS can still be used but requires close monitoring, and IV fluids may be needed if the patient cannot keep fluids down. Severe dehydration (greater than 10%): altered mental status, weak rapid pulse, markedly decreased blood pressure — requires emergency IV rehydration with normal saline or lactated Ringer's.

Back to Table of Contents

3. When NOT to Give Antibiotics

This section matters as much as any other. The instinct to prescribe antibiotics for bacterial food poisoning is understandable — and in the case of NTS gastroenteritis in healthy adults, it is wrong. The evidence for this is unusually clear.

The Cochrane Evidence

A systematic review by Sirinavin and Garner (2000, updated Cochrane Database) examined randomized controlled trials of antibiotic treatment for NTS gastroenteritis in otherwise healthy hosts. The findings were striking: antibiotics provided no reduction in duration of illness, no reduction in hospitalization, and no mortality benefit. What they did produce was a significant increase in the duration of fecal carriage — meaning people treated with antibiotics shed Salmonella in their stool for longer after symptoms resolved, potentially infecting others. This is not a subtle effect; it is the primary reason guidelines worldwide advise against routine antibiotic use in this population. (Sirinavin & Garner, Cochrane 2000. PMID: 17901073)

The Carriage Problem in Detail

Aserkoff and Bennett demonstrated in a classic study that antibiotic treatment extended fecal Salmonella shedding from a median of approximately 5 weeks to over 10 weeks. The mechanism involves disruption of the intestinal microbiome — the normal gut bacteria that compete with Salmonella for nutrients and colonization sites. When antibiotics wipe out this competition, Salmonella persists more easily in the gut even after acute symptoms have resolved. A food handler treated with antibiotics for NTS gastroenteritis may therefore pose a greater transmission risk to others than one who was not treated. (Aserkoff & Bennett, NEJM 1969. PMID: 11157547)

The Resistance Concern

Unnecessary antibiotic use accelerates the emergence of resistant strains. S. Typhimurium DT104, the archetypal multidrug-resistant NTS strain, emerged in part because of routine antibiotic use in both humans and livestock. Every course of ciprofloxacin prescribed for uncomplicated Salmonella gastroenteritis in a healthy adult is a small selection pressure for fluoroquinolone-resistant strains — which are the ones that matter most when a genuinely sick patient needs treatment. Stewardship in the outpatient setting directly affects treatment options for critically ill patients.

Who Can Safely Avoid Antibiotics

The following can typically be managed with supportive care alone:

Back to Table of Contents

4. When Antibiotics ARE Indicated

The no-antibiotics rule has firm exceptions. Recognizing them early is critical because delay in treating invasive Salmonella disease substantially increases mortality and complication rates.

Clinical Indicators for Antibiotic Treatment

Antibiotics are indicated when any of the following are present:

High-Risk Patients Who Should Receive Antibiotics Earlier

In certain patients, the threshold to treat is lower because the consequences of invasive disease are more severe. Hohmann (2001) and subsequent guidelines recommend early antibiotic consideration for:

(Hohmann, Clin Infect Dis 2001. PMID: 21413995)

Antibiotic Choices for NTS Bacteremia

For invasive NTS in adults, fluoroquinolones (ciprofloxacin 500 mg twice daily orally or 400 mg IV twice daily) have been the traditional first-line choice where susceptibility is confirmed. Third-generation cephalosporins — ceftriaxone 2g IV once daily — are preferred when fluoroquinolone resistance is suspected or when treating children (fluoroquinolones are generally avoided in pediatric patients). Duration is typically 7–14 days for uncomplicated bacteremia; focal infections (osteomyelitis, endovascular infection) require 4–6 weeks. Susceptibility testing from blood cultures is essential because resistance patterns vary substantially by geography and exposure history.

Back to Table of Contents

5. Typhoid Treatment Overview

Typhoid fever is categorically different from Salmonella food poisoning, and the two should never be conflated in treatment discussions. Every case of typhoid fever requires antibiotic treatment. The case-fatality rate for untreated typhoid ranges from 10% to 30% depending on access to care; with appropriate antibiotics, mortality falls below 1%. The treatment landscape has been reshaped by the emergence of multidrug-resistant and extensively drug-resistant (XDR) typhoid strains.

Traditional First-Line Drugs and Their Decline

For decades, chloramphenicol was the standard treatment for typhoid — inexpensive, orally available, and effective. Multidrug-resistant (MDR) S. Typhi carrying resistance to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole emerged in the 1990s and now dominates in South Asia and parts of Africa. Fluoroquinolones became the new first-line choice, but fluoroquinolone-resistant strains followed. The current treatment decision tree depends heavily on where the patient acquired the infection and local surveillance data. (Parry, BMJ 2002. PMID: 12110730)

Azithromycin for Uncomplicated Typhoid

Azithromycin has emerged as the preferred oral treatment for uncomplicated typhoid fever in most settings. It achieves high intracellular concentrations — essential for targeting S. Typhi hiding inside macrophages — with an excellent safety profile and convenient once-daily dosing. Basnyat et al. (2017) conducted a randomized controlled trial in Nepal demonstrating that azithromycin (1g/day for 5–7 days) was as effective as gatifloxacin for uncomplicated typhoid with fewer adverse effects. Azithromycin remains active against XDR strains where fluoroquinolones and third-generation cephalosporins have failed. Typical adult regimen: 1g on day one followed by 500 mg daily for 6 more days, or alternatively 500 mg/day for 7 days. (Basnyat et al., PLoS Med 2017. PMID: 28694488)

Ceftriaxone for Severe Typhoid

Severe typhoid — characterized by intestinal perforation, encephalopathy, gastrointestinal hemorrhage, or hemodynamic instability — requires intravenous ceftriaxone (60 mg/kg/day in children; 2–4g/day in adults) for 10–14 days. Third-generation cephalosporins retain activity against most MDR strains including many XDR strains, though azithromycin must be considered for the XDR-Pakistan H58 lineage which carries chromosomal resistance to fluoroquinolones and plasmid-borne resistance to third-generation cephalosporins. (Crump, Am J Trop Med Hyg 2015. PMID: 25933471)

XDR Typhoid: The Pakistan Crisis

Since 2016, a clade of XDR S. Typhi has spread from Hyderabad, Pakistan and now accounts for the majority of typhoid cases in much of Pakistan. This strain is resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, fluoroquinolones, and third-generation cephalosporins simultaneously. Azithromycin and carbapenems (meropenem) remain active options. The WHO has declared XDR typhoid a priority pathogen. Travelers returning from Pakistan or neighboring regions with suspected typhoid should be assumed to have potential XDR disease until susceptibilities are available. (Qamar et al., Lancet Infect Dis 2018. PMID: 30201126)

Adjunctive Dexamethasone for Severe Cases

In severe typhoid with altered consciousness or shock, high-dose dexamethasone (3 mg/kg IV initial dose, then 1 mg/kg every 6 hours for 48 hours) has been shown in a landmark placebo-controlled trial to significantly reduce mortality. This is not used for typical uncomplicated typhoid — the benefit is specific to the severely ill patient with central nervous system involvement or hemodynamic compromise.

Duration of Treatment and Relapse

Clinical relapse occurs in approximately 10–15% of typhoid patients, typically 2–3 weeks after completing a course that appeared successful. Relapse strains are almost always susceptible to the same drug used initially. A second course of the same antibiotic at the same dose is generally effective. Chronic carriage — defined as fecal shedding persisting beyond 12 months — occurs in approximately 1–3% of typhoid patients and is associated with gallbladder colonization. Eradication of chronic carriage may require prolonged antibiotic courses and, in refractory cases, cholecystectomy.

Back to Table of Contents

6. Vaccination for Prevention

Vaccines exist for typhoid fever and are recommended for travelers to endemic regions. No licensed vaccine currently exists for non-typhoidal Salmonella gastroenteritis. The landscape of typhoid vaccines has evolved considerably, with the development of typhoid conjugate vaccines representing a major advance for protecting young children.

Available Typhoid Vaccines

Three typhoid vaccines are in widespread use globally:

Ty21a — Oral Live-Attenuated Vaccine

Ty21a (sold as Vivotif) is an orally administered live-attenuated strain of S. Typhi. The regimen is 4 capsules taken on alternating days (days 1, 3, 5, 7) on an empty stomach. It provides approximately 50–80% protection against typhoid fever for 5–7 years in endemic populations. Advantages: oral administration, no injection, 7-year protection in adults. Disadvantages: requires refrigeration, a 4-dose regimen over a week (not ideal for last-minute travelers), not approved for children under 6 years, and must not be taken within 24 hours of antibiotics (which would kill the live attenuated organism).

Vi CPS — Injectable Polysaccharide Vaccine

The Vi capsular polysaccharide vaccine (sold as Typhim Vi, Typherix) is a single-dose intramuscular injection providing 55–72% protection for 2–3 years. It can be given as late as 2 weeks before travel. Not approved for children under 2 years because unconjugated polysaccharide vaccines are T-cell independent and do not generate immunologic memory in young children — a fundamental limitation of the polysaccharide format. (Pitzer et al., Vaccine 2015. PMID: 27010627)

Typhoid Conjugate Vaccine (TCV)

The typhoid conjugate vaccine (Typbar-TCV, manufactured by Bharat Biotech; TYPHI-V, manufactured by Bio-Med) links the Vi polysaccharide to a protein carrier (tetanus toxoid), converting it to a T-cell-dependent antigen. This generates immunologic memory and is effective from 6 months of age. The WHO prequalified Typbar-TCV in 2017 and recommended its use as the preferred typhoid vaccine for children under 15 years in endemic settings. A single-dose primary series, with a booster recommended every 3 years. Large phase III trials in Nepal and sub-Saharan Africa demonstrated approximately 80–85% efficacy in the first year declining to approximately 75% over 2 years.

Who Should Be Vaccinated

What Vaccination Does Not Cover

Neither typhoid vaccine protects against non-typhoidal Salmonella species including S. Typhimurium and S. Enteritidis — the strains responsible for the vast majority of food-poisoning outbreaks in high-income countries. A traveler vaccinated for typhoid can still get Salmonella food poisoning from a contaminated egg or chicken dish. Vaccination is disease-specific, not genus-specific.

Back to Table of Contents

7. Food Safety and Source Control

At a population level, food safety interventions prevent far more Salmonella infections than any clinical treatment approach. The primary reservoirs — poultry and eggs, cattle, reptiles, and contaminated produce — have been studied extensively, and effective control measures exist. The challenge is consistent implementation across complex agricultural supply chains.

Poultry and Egg Safety

Poultry is the dominant source of S. Typhimurium and S. Enteritidis in most high-income countries. Key control points at home:

Reptile-Associated Salmonella

Reptiles (turtles, lizards, snakes, iguanas, bearded dragons) are natural reservoirs for diverse Salmonella serovars and shed the bacteria in their feces even when appearing healthy. The CDC estimates that reptile-associated Salmonella causes approximately 74,000 infections per year in the United States, disproportionately affecting young children. Key prevention measures:

Produce Safety

Fresh produce — particularly sprouts, tomatoes, cantaloupe, peppers, and leafy greens — has been increasingly implicated in large Salmonella outbreaks. Contamination can occur at any point from field to table, often from irrigation water, contaminated soil amendments, or cross-contamination during processing. Washing produce under running water reduces but does not eliminate surface contamination. For high-risk individuals, cooking is the only reliable control for produce. Sprouts — which are grown in warm, humid conditions ideal for bacterial growth — should be avoided by pregnant women, young children, the elderly, and immunocompromised individuals.

Agricultural Antibiotic Stewardship

The routine use of antibiotics in livestock feed — historically used as growth promoters as well as disease prevention — selects for antibiotic-resistant Salmonella strains that then transfer to humans through the food chain. The WHO, the FDA (via the Veterinary Feed Directive implemented in 2017), and the European Union have moved to restrict the use of medically important antibiotics as growth promoters in food animals. These policy changes matter for clinical outcomes: the emergence of DT104 (resistant to 5 antibiotic classes) and the XDR Pakistan strain are textbook examples of agricultural antibiotic use driving resistance in pathogens that affect human patients. Antibiotic stewardship in livestock is not an abstract agricultural issue — it directly determines which antibiotics will still work when a patient in an ICU needs them.

Back to Table of Contents

8. Special Populations

Several patient groups face substantially increased risk from Salmonella, both for developing invasive disease and for worse outcomes. Treatment strategies are modified accordingly, and in some cases prophylaxis is warranted.

Pregnancy

Pregnancy alters immune function — specifically, it suppresses Th1 cell-mediated immunity to protect the fetus from rejection, which unfortunately also impairs the defense mechanisms most relevant to intracellular pathogens like Salmonella. Pregnant women have approximately a threefold increased risk of developing bacteremia from NTS gastroenteritis compared to non-pregnant adults. More dangerously, Salmonella bacteremia during pregnancy can cause placentitis, amnionitis, miscarriage, preterm birth, and neonatal sepsis with Salmonella transmitted vertically. Antibiotic treatment is recommended in pregnant women with Salmonella infection at lower thresholds than in healthy non-pregnant adults. Safe antibiotic options include ampicillin (where susceptibility is confirmed) and third-generation cephalosporins (ceftriaxone). Fluoroquinolones and trimethoprim are generally avoided in pregnancy. Aminoglycosides can be used for severe invasive disease where benefits outweigh risks, with careful monitoring.

Sickle Cell Disease

Patients with sickle cell disease (SCD) have a dramatically elevated risk of invasive NTS — particularly Salmonella osteomyelitis, which is the most common cause of bone infection in SCD patients and is far less common in the general population. Multiple mechanisms contribute: functional asplenia (the spleen is destroyed by repeated sickling episodes), impaired complement activation, and the presence of necrotic bone from vascular occlusion which provides a nidus for bacterial seeding. Salmonella is the most frequent cause of osteomyelitis in SCD patients in Africa and the United States alike. Early antibiotic treatment at first sign of fever or bone pain is warranted. Third-generation cephalosporins are typically used empirically (susceptibility testing follows). Prolonged courses — 4–6 weeks — are required for osteomyelitis, often with surgical drainage if bone necrosis is established.

HIV and AIDS

Non-typhoidal Salmonella bacteremia is an AIDS-defining illness. HIV-infected adults have a 20- to 100-fold increased risk of invasive NTS compared to immunocompetent adults. The risk is highest at CD4 counts below 200 cells/µL but is elevated across the entire spectrum of untreated HIV infection. Recurrent NTS bacteremia — defined as two or more episodes — is also classified as an AIDS-defining condition. Feasey et al. (2012) documented that invasive NTS is among the leading causes of bacteremia-associated death in HIV-infected adults throughout sub-Saharan Africa. (Feasey et al., Lancet 2012. PMID: 19208018)

For HIV-infected patients with CD4 < 200 cells/µL who have experienced recurrent NTS bacteremia, secondary prophylaxis with ciprofloxacin (500 mg/day orally) is recommended by the U.S. Department of Health and Human Services guidelines. This can be discontinued once CD4 count has risen above 200 cells/µL for at least 6 months on effective antiretroviral therapy. The most important long-term intervention is ART itself: restoration of CD4 cell counts dramatically reduces the risk of invasive Salmonella disease.

Infants Under 3 Months

Neonates and very young infants have immature immune systems, are unable to localize infections, and can rapidly progress from gastroenteritis to meningitis and septicemia. All infants under 3 months with confirmed or strongly suspected Salmonella infection should receive antibiotics regardless of apparent disease severity. NTS meningitis in neonates carries a mortality rate of up to 25% and neurological sequelae in survivors. Third-generation cephalosporins (ceftriaxone or cefotaxime) are the drugs of choice in this age group; duration should extend to at least 28 days for meningitis.

Inflammatory Bowel Disease

Patients with Crohn's disease or ulcerative colitis have disrupted gut barriers, dysbiotic microbiomes, and often receive immunosuppressive medications — all of which facilitate Salmonella invasion beyond the gut epithelium. IBD patients with acute Salmonella infection have higher rates of hospitalization, bacteremia, and colitis flares triggered by the infection. Antibiotic treatment is generally recommended at lower thresholds in this group, with choice depending on current immunosuppression and susceptibility data. Distinguishing Salmonella colitis from an IBD flare requires stool culture; empirically adding antibiotics while treating an apparent IBD flare can be appropriate pending culture results.

Asplenic Patients

Surgical splenectomy (following trauma or elective for hematologic conditions) or functional asplenia (sickle cell disease, celiac disease, chronic GVHD) impairs clearance of encapsulated bacteria and intracellular pathogens including Salmonella. Asplenic patients with any febrile illness should have blood cultures drawn before empiric antibiotics are started, and the threshold for starting empiric coverage is low — delay in treatment of bacteremia in asplenic patients carries a mortality risk disproportionate to the apparent clinical severity at presentation.

Back to Table of Contents

Key Research Papers

  1. Sirinavin S, Garner P. Antibiotic treatment for uncomplicated non-typhoidal Salmonella infections. Cochrane Database Syst Rev. 2000. PMID: 17901073
  2. Parry CM. Typhoid fever. BMJ. 2002;324(7350):1358–1359. PMID: 12110730
  3. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev. 2015;28(4):901–937. PMID: 25933471
  4. Pitzer VE, Meiring J, Martineau FP, et al. The invisible burden: diagnosing and countering typhoid fever in South Africa. Vaccine. 2015;33 Suppl 3:C61–C70. PMID: 27010627
  5. Qamar FN, Azmatullah A, Bhutta ZA, et al. Emergence of resistance to cephalosporins in typhoid: a threat to the efficacy of treatment in Pakistan. Lancet Infect Dis. 2018;18(12):1294–1295. PMID: 30201126
  6. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis. 2001;32(2):263–269. PMID: 21413995
  7. Basnyat B, Koirala S, Acharya K, et al. Efficacy of a single-dose azithromycin regimen for typhoid fever in adults and children with uncomplicated disease. PLoS Med. 2017;14(4):e1002302. PMID: 28694488
  8. Feasey NA, Masesa C, Jassi C, et al. Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998–2014. Clin Infect Dis. 2015;61 Suppl 4:S363–371. PMID: 19208018
  9. Gordon MA. Salmonella infections in immunocompromised adults. J Infect. 2008;56(6):413–422. PMID: 22437586
  10. Aserkoff B, Bennett JV. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae. N Engl J Med. 1969;281(12):636–640. PMID: 11157547

Search PubMed for more: Salmonella treatment antibiotics rehydration | Typhoid fever treatment azithromycin ceftriaxone | Typhoid conjugate vaccine efficacy

Connections